Search

Sartorius Stedim Biotech.

Aperta

SettoreFinanza

212.9 -0.65

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

209.2

Massimo

215.5

Metriche Chiave

By Trading Economics

Entrata

-28M

64M

Vendite

-39M

706M

P/E

Media del settore

79.114

26.043

EPS

0.94

Margine di Profitto

9.097

Dipendenti

10,134

EBITDA

16M

218M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+11.99% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

691M

21B

Apertura precedente

213.55

Chiusura precedente

212.9

Notizie sul Sentiment di mercato

By Acuity

29%

71%

76 / 525 Classifica in Finance

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Sartorius Stedim Biotech. Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

10 gen 2026, 00:16 UTC

Acquisizioni, Fusioni, Takeovers

Edwards Lifesciences Drops Merger With JenaValve

11 gen 2026, 23:46 UTC

Discorsi di Mercato

Gold Rises Amid Geopolitical Risks -- Market Talk

11 gen 2026, 23:35 UTC

Discorsi di Mercato

Oil Rises Amid Middle East Tensions -- Market Talk

11 gen 2026, 23:25 UTC

Utili

Stock Futures Drift Lower With Bank Earnings, CPI on Tap -- Barrons.com

11 gen 2026, 22:05 UTC

Discorsi di Mercato

Iron Ore Outlook Weighed by Soft China Steel Markets, Rising Supply -- Market Talk

10 gen 2026, 12:00 UTC

Acquisizioni, Fusioni, Takeovers

Copper Is the Prize in Mining Megadeals -- WSJ

10 gen 2026, 09:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

10 gen 2026, 09:20 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Basic Materials Roundup: Market Talk

10 gen 2026, 09:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

9 gen 2026, 22:18 UTC

Discorsi di Mercato

Changes Needed for Exxon Mobil to Return to Venezuela -- Market Talk

9 gen 2026, 21:50 UTC

Discorsi di Mercato

Energy & Utilities Roundup: Market Talk

9 gen 2026, 21:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Basic Materials Roundup: Market Talk

9 gen 2026, 21:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

9 gen 2026, 21:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

9 gen 2026, 21:43 UTC

Utili
Acquisizioni, Fusioni, Takeovers

These Stocks Moved the Most Today: Oklo, Vistra, Opendoor, Intel, GM, Revolution Medicines, Tilray, and More -- Barrons.com

9 gen 2026, 20:39 UTC

Discorsi di Mercato

GE Vernova Seen With Rising Concern of Overcapacity -- Market Talk

9 gen 2026, 20:38 UTC

Discorsi di Mercato

U.S. Natural Gas Falls on Loose Supply Outlook -- Market Talk

9 gen 2026, 20:36 UTC

Acquisizioni, Fusioni, Takeovers

Cathie Wood's ARK Invest Takes a New Stake in Broadcom -- and Sold Another Hot Stock -- Barrons.com

9 gen 2026, 20:30 UTC

Discorsi di Mercato

Oil Makes Weekly Gains in Geopolitically Driven Trade -- Market Talk

9 gen 2026, 20:15 UTC

Discorsi di Mercato

Chevron Seen With Modest Opportunity to Boost Venezuela Oil Production -- Market Talk

9 gen 2026, 20:07 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

9 gen 2026, 20:07 UTC

Discorsi di Mercato

Goldman Sachs' Pivot from Consumer Lending Seen as Positive -- Market Talk

9 gen 2026, 19:58 UTC

Acquisizioni, Fusioni, Takeovers

Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ

9 gen 2026, 19:42 UTC

Discorsi di Mercato

Adobe Seen With Weak Competitive Position Compared to Rivals -- Market Talk

9 gen 2026, 19:38 UTC

Acquisizioni, Fusioni, Takeovers

Wolters Kluwer Acquires StandardFusion >WTKWY

9 gen 2026, 19:31 UTC

Utili

Qualcomm Stock Falls After Downgrade. The Apple Supplier Has an iPhone Problem. -- Barrons.com

9 gen 2026, 19:28 UTC

Utili

Apple Stock Set to Break Brutal Losing Streak. Why It Remains Evercore's 'Top Pick.' -- Barrons.com

9 gen 2026, 18:30 UTC

Discorsi di Mercato

U.S. Oil Rig Count Falls by 3 to 409 -- Market Talk

9 gen 2026, 18:23 UTC

Discorsi di Mercato

Reports of Canada Oil Sector's Demise Are Premature -- Market Talk

9 gen 2026, 17:20 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Basic Materials Roundup: Market Talk

Sartorius Stedim Biotech. Previsione

Obiettivo di Prezzo

By TipRanks

11.99% in crescita

Previsioni per 12 mesi

Media 240 EUR  11.99%

Alto 260 EUR

Basso 210 EUR

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Sartorius Stedim Biotech. - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

7 ratings

5

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

202.7 / 211.7Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Strong Bullish Evidence

Sentiment

By Acuity

76 / 525 Classifica in Finanza

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
help-icon Live chat